Concepedia

Vijay Yerroju

VY

Statistics

Publications

4

Citations

149

H-Index

4

Active since

2022

Affiliations

Biological E (India)(Current)

Translational Health Science and Technology Institute

St. Theresa’s Multi-Speciality Hospital

All India Institute of Medical Sciences

ESIC Hospital

Vijay Yerroju is an author at Biological E (India) specializing in vaccine efficacy, vaccine safety, and immunology.

ORCID

Publications per year

2022–2023

4

Publications

4

Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials

Subhash Thuluva, Vikram Paradkar, Subba Reddy Gunneri et al. · EBioMedicine · 2022 · 74 citations · Full text

, , +16

Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Vaccine · 2022 · 33 citations

, , +15

Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial

Subhash Thuluva, Vikram Paradkar, SubbaReddy Gunneri et al. · Human Vaccines & Immunotherapeutics · 2023 · 32 citations · Full text

, , +17

Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies

Subhash Thuluva, Vikram Paradkar, Kishore Turaga et al. · medRxiv · 2022 · 10 citations · Full text

, , +17

1–4 of 4